Drug
Ald518
Ald518: highest development phase Phase 2, developed by CSL. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- CSL
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALD518 NCT01403064 | Phase 2 | Oral Mucositis |
| ALD518 NCT00866970 | Phase 2 | NSCLC |
| ALD518 NCT00867516 | Phase 2 | Arthritis, Rheumatoid |
Latest
No recent events.
Follow Ald518 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.